Left Ventricular Dysfunction in Arrhythmogenic Cardiomyopathy: Association With Exercise Exposure, Genetic Basis, and

Øyvind H Lie1,2, Monica Chivulescu1,2, Christine Rootwelt-Norberg1,2

  • 1Department of Cardiology Oslo University Hospital, Rikshospitalet Norway.

Insights

Greater exercise is linked to worse left ventricular (LV) function in arrhythmogenic cardiomyopathy (AC) patients at diagnosis. LV function decline predicts arrhythmias, especially in desmoplakin genotype carriers.

Area of Science:

  • Cardiology
  • Genetics
  • Cardiovascular Imaging

Background:

  • Arrhythmogenic cardiomyopathy (AC) presents with biventricular dysfunction, exercise intolerance, and high risk of ventricular tachyarrhythmias and sudden death.
  • Factors influencing left ventricular (LV) disease manifestation and prognosis in AC remain incompletely understood.
  • Left ventricular dysfunction is a critical determinant of adverse outcomes in AC.

Purpose of the Study:

  • To investigate the association between exercise exposure and genotype with LV dysfunction in AC.
  • To determine the impact of LV disease progression on the risk of adverse arrhythmic events.
  • To identify predictors of LV dysfunction progression and subsequent ventricular tachyarrhythmias in AC.

Main Methods:

  • Longitudinal study of 168 AC patients with comprehensive echocardiographic follow-up (7.6 years).
  • Assessment of LV function using global longitudinal strain (GLS) and correlation with exercise data.
  • Analysis of genetic data, focusing on desmoplakin genotype, and its interaction with LV function progression.

Main Results:

  • Higher exercise exposure correlated with worse baseline LV function (GLS worsening per 5 MET-hours/week, P=0.02).
  • LV function significantly worsened over time (0.08% per year, P<0.001), with accelerated progression in desmoplakin genotype patients (P<0.001).
  • Deterioration in LV function predicted incident ventricular tachyarrhythmias (OR 1.1 per 1% GLS worsening, P=0.02).

Conclusions:

  • Exercise exposure is associated with baseline LV dysfunction but not the rate of LV progression in AC.
  • LV dysfunction progression is most pronounced in patients with desmoplakin genotypes.
  • Monitoring LV function deterioration is crucial for risk stratification of ventricular tachyarrhythmias in AC.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
121
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
185
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
125
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
104
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
166
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
160